中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1030-1036

Research advances in prognostic score models and biomarkers for acute-on-chronic liver failure

DOI: 10.12449/JCH250605

  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases，The First Affiliated Hospital，Zhejiang University School of Medicine. Hangzhou 310003，China

Research funding:

National Key Research and Development Program of China (2022YFC2304500)

More Information
  • Corresponding author: SHI Yu， zjushiyu@zju.edu.cn （ORCID： 0000-0002-9392-7176）
  • Received Date: 2025-03-26
  • Accepted Date: 2025-04-22
  • Published Date: 2025-06-25
    Abstract
  • Acute-on-chronic liver failure （ACLF） is a complex clinical syndrome， and early identification and accurate prognostic evaluation are of great importance for patient treatment and management. In recent years， with in-depth research on the pathogenesis of ACLF， multiple prognostic biomarkers have been proposed and used in clinical practice. This article systematically reviews the research advances in prognostic biomarkers for ACLF from the aspects of clinical predictive models， immunological biomarkers， metabolic biomarkers， genetic and epigenetic biomarkers， microbiome-related biomarkers， and emerging technologies such as artificial intelligence and multi-omics， and it also discusses the value and application prospects of these biomarkers in the prognostic evaluation of ACLF and proposes future research directions， in order to provide a scientific and comprehensive reference for clinicians， guide individualized treatment and management of ACLF patients， and finally improve the clinical outcomes of patients.

     

    • FullText(HTML)
  • loading
    • References(58)
  • [1]
    MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31( 4): 864- 871. DOI: 10.1053/he.2000.5852.
    [2]
    LI P, LIANG X, LUO JJ, et al. Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: An observational cohort study[J]. Lancet Reg Health West Pac, 2022, 32: 100638. DOI: 10.1016/j.lanwpc.2022.100638.
    [3]
    KULKARNI AV, SARIN SK. Acute-on-chronic liver failure-steps towards harmonization of the definition![J]. J Hepatol, 2024, 81( 2): 360- 366. DOI: 10.1016/j.jhep.2024.03.036.
    [4]
    YU X, LI H, TAN WT, et al. Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis[J]. Front Microbiol, 2022, 13: 1013439. DOI: 10.3389/fmicb.2022.1013439.
    [5]
    LI JQ, LIANG X, YOU SL, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75( 5): 1104- 1115. DOI: 10.1016/j.jhep.2021.05.026.
    [6]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
    [7]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144( 7): 1426- 1437, 1437. e1- 1437. e9. DOI: 10.1053/j.gastro.2013.02.042.
    [8]
    WU TZ, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67( 12): 2181- 2191. DOI: 10.1136/gutjnl-2017-314641.
    [9]
    QIAO L, TAN WT, WANG XB, et al. Different effects of total bilirubin on 90-day mortality in hospitalized patients with cirrhosis and advanced fibrosis: A quantitative analysis[J]. Front Med(Lausanne), 2021, 8: 704452. DOI: 10.3389/fmed.2021.704452.
    [10]
    WANG Y, DONG FC, SUN SN, et al. Increased INR values predict accelerating deterioration and high short-term mortality among patients hospitalized with cirrhosis or advanced fibrosis[J]. Front Med(Lausanne), 2021, 8: 762291. DOI: 10.3389/fmed.2021.762291.
    [11]
    ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74( 3): 670- 685. DOI: 10.1016/j.jhep.2020.11.048.
    [12]
    MOREAU R, TONON M, KRAG A, et al. EASL clinical practice guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 2): 461- 491. DOI: 10.1016/j.jhep.2023.04.021.
    [13]
    GAO FY, LI XS, GENG MF, et al. Pretreatment neutrophil-lymphocyte ratio: An independent predictor of survival in patients with hepatocellular carcinoma[J]. Medicine(Baltimore), 2015, 94( 11): e639. DOI: 10.1097/MD.0000000000000639.
    [14]
    NIELSEN MC, HVIDBJERG GANTZEL R, CLÀRIA J, et al. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure[J]. Cells, 2020, 9( 5): 1175. DOI: 10.3390/cells9051175.
    [15]
    ARIZA X, GRAUPERA I, COLL M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis[J]. J Hepatol, 2016, 65( 1): 57- 65. DOI: 10.1016/j.jhep.2016.03.002.
    [16]
    TREBICKA J, AGUILAR F, FARIAS AQ, et al. Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis[J]. Gut, 2025. DOI: 10.1136/gutjnl-2024-333876.[ Online ahead of print]
    [17]
    O’BRIEN AJ, FULLERTON JN, MASSEY KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J]. Nat Med, 2014, 20( 5): 518- 523. DOI: 10.1038/nm.3516.
    [18]
    ANTONIADES CG, BERRY PA, DAVIES ET, et al. Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure[J]. Hepatology, 2006, 44( 1): 34- 43. DOI: 10.1002/hep.21240.
    [19]
    ZACCHERINI G, AGUILAR F, CARACENI P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF[J]. J Hepatol, 2021, 74( 5): 1117- 1131. DOI: 10.1016/j.jhep.2020.11.035.
    [20]
    LI ZW, TU S, YU X, et al. Hepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failure[J]. Virulence, 2024, 15( 1): 2404953. DOI: 10.1080/21505594.2024.2404953.
    [21]
    WEISS E, de la PEÑA-RAMIREZ C, AGUILAR F, et al. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: The metabolomic prognostic models(CLIF-C MET)[J]. Gut, 2023, 72( 8): 1581- 1591. DOI: 10.1136/gutjnl-2022-328708.
    [22]
    MOREAU R, CLÀRIA J, AGUILAR F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF[J]. J Hepatol, 2020, 72( 4): 688- 701. DOI: 10.1016/j.jhep.2019.11.009.
    [23]
    CLÀRIA J, MOREAU R, FENAILLE F, et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis[J]. Hepatology, 2019, 69( 4): 1686- 1701. DOI: 10.1002/hep.30363.
    [24]
    LÓPEZ-VICARIO C, CHECA A, URDANGARIN A, et al. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis[J]. J Hepatol, 2020, 73( 4): 817- 828. DOI: 10.1016/j.jhep.2020.03.046.
    [25]
    ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
    [26]
    TAN WT, XIA J, DAN YJ, et al. Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure[J]. Gut, 2018, 67( 4): 757- 766. DOI: 10.1136/gutjnl-2016-313035.
    [27]
    DENG GH, ZHOU GQ, ZHANG R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers[J]. Gastroenterology, 2008, 134( 3): 716- 726. DOI: 10.1053/j.gastro.2007.12.044.
    [28]
    YAN Z, TAN W, ZHAO W, et al. Regulatory polymorphisms in the IL-10 gene promoter and HBV-related acute liver failure in the Chinese population[J]. J Viral Hepat, 2009, 16( 11): 775- 783. DOI: 10.1111/j.1365-2893.2009.01139.x.
    [29]
    AJMERA V, HUANG HL, DAO D, et al. Host genetic variant in CXCL16 may be associated with hepatitis B virus-related acute liver failure[J]. Cell Mol Gastroenterol Hepatol, 2019, 7( 2): 477- 479. e 4. DOI: 10.1016/j.jcmgh.2018.09.018.
    [30]
    ALCARAZ-QUILES J, TITOS E, CASULLERAS M, et al. Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure[J]. Hepatology, 2017, 65( 1): 202- 216. DOI: 10.1002/hep.28896.
    [31]
    WEN Y, PENG SF, FU L, et al. Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Hepatobiliary Pancreat Dis Int, 2018, 17( 2): 126- 132. DOI: 10.1016/j.hbpd.2018.03.004.
    [32]
    ZHAO J, FAN YC, LIU XY, et al. Hypermethylation of the galectin-3 promoter is associated with poor prognosis of acute-on-chronic hepatitis B liver failure[J]. Dig Liver Dis, 2017, 49( 6): 664- 671. DOI: 10.1016/j.dld.2017.01.158.
    [33]
    FAN XP, DOU CY, FAN YC, et al. Methylation status of the estrogen receptor 1 promoter predicts poor prognosis of acute-on-chronic hepatitis B liver failure[J]. Rev Esp Enferm Dig, 2017, 109( 12): 818- 827. DOI: 10.17235/reed.2017.4426/2016.
    [34]
    ZHOU TH, SUN Y, LI M, et al. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway[J]. Cell Death Dis, 2018, 9( 6): 590. DOI: 10.1038/s41419-018-0670-2.
    [35]
    CAO ZJ, LI FD, XIANG XG, et al. Circulating cell death biomarker: Good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure[J]. Sci Rep, 2015, 5: 14240. DOI: 10.1038/srep14240.
    [36]
    ADEBAYO D, MORABITO V, ANDREOLA F, et al. Mechanism of cell death in acute-on-chronic liver failure: A clinico-pathologic-biomarker study[J]. Liver Int, 2015, 35( 12): 2564- 2574. DOI: 10.1111/liv.12850.
    [37]
    STÄRKEL P, SCHNABL B. Bidirectional communication between liver and gut during alcoholic liver disease[J]. Semin Liver Dis, 2016, 36( 4): 331- 339. DOI: 10.1055/s-0036-1593882.
    [38]
    LECLERCQ S, CANI PD, NEYRINCK AM, et al. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects[J]. Brain Behav Immun, 2012, 26( 6): 911- 918. DOI: 10.1016/j.bbi.2012.04.001.
    [39]
    CHEN YF, GUO J, QIAN GR, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality[J]. J Gastroenterol Hepatol, 2015, 30( 9): 1429- 1437. DOI: 10.1111/jgh.12932.
    [40]
    BAJAJ JS, O’LEARY JG, REDDY KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: The North American consortium for the study of end-stage liver disease(NACSELD) experience[J]. Hepatology, 2012, 56( 6): 2328- 2335. DOI: 10.1002/hep.25947.
    [41]
    LLORENTE C, JEPSEN P, INAMINE T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus[J]. Nat Commun, 2017, 8( 1): 837. DOI: 10.1038/s41467-017-00796-x.
    [42]
    TREBICKA J, FERNANDEZ J, PAPP M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol, 2020, 73( 4): 842- 854. DOI: 10.1016/j.jhep.2020.06.013.
    [43]
    RIDLON JM, HARRIS SC, BHOWMIK S, et al. Consequences of bile salt biotransformations by intestinal bacteria[J]. Gut Microbes, 2016, 7( 1): 22- 39. DOI: 10.1080/19490976.2015.1127483.
    [44]
    ZHANG Y, ZHAO RH, SHI D, et al. Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B[J]. Liver Int, 2019, 39( 7): 1207- 1216. DOI: 10.1111/liv.14097.
    [45]
    LEE S, AREFAINE B, BEGUM N, et al. Oral-gut microbiome interactions in advanced cirrhosis: Characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance[J]. J Hepatol, 2025, 82( 4): 622- 633. DOI: 10.1016/j.jhep.2024.09.046.
    [46]
    HU CH, JIANG N, ZHENG J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 12): 1253- 1263. DOI: 10.1002/jhbp.1112.
    [47]
    LI TZ, XU MM, KONG M, et al. Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure[J]. Sci Rep, 2021, 11( 1): 12593. DOI: 10.1038/s41598-021-92087-1.
    [48]
    WACKENTHALER A, MOLIÈRE S, ARTZNER T, et al. Pre-operative CT scan helps predict outcome after liver transplantation for acute-on-chronic grade 3 liver failure[J]. Eur Radiol, 2022, 32( 1): 12- 21. DOI: 10.1007/s00330-021-08131-1.
    [49]
    LAN LJ, LU XF, SHU J. T2 values for diagnosing acute-on-chronic liver failure in hepatitis B patients[J]. Curr Med Imaging, 2021, 17( 1): 129- 135. DOI: 10.2174/1573405616666200625152357.
    [50]
    LIU CX, SHEN ZJ, MA H, et al. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure[J]. Eur Radiol, 2022, 32( 5): 3006- 3015. DOI: 10.1007/s00330-021-08440-5.
    [51]
    DU YN, GUAN CS, LV ZB, et al. T2-weighted imaging and dynamic contrast-enhanced imaging in predicting the prognosis in patients with acute-on-chronic liver failure[J]. BMC Gastroenterol, 2023, 23( 1): 285. DOI: 10.1186/s12876-023-02920-2.
    [52]
    JIN JY, ZHENG YB, ZHENG J, et al. 2D shear wave elastography combined with MELD improved prognostic accuracy in patients with acute-on-chronic hepatitis B liver failure[J]. Eur Radiol, 2018, 28( 10): 4465- 4474. DOI: 10.1007/s00330-018-5336-z.
    [53]
    TONON M, MOREAU R. Using machine learning for predicting outcomes in ACLF[J]. Liver Int, 2022, 42( 11): 2354- 2355. DOI: 10.1111/liv.15399.
    [54]
    TREBICKA J, BORK P, KRAG A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 167- 180. DOI: 10.1038/s41575-020-00376-3.
    [55]
    VERMA N, CHOUDHURY A, SINGH V, et al. APASL-ACLF Research Consortium-Artificial Intelligence(AARC-AI) model precisely predicts outcomes in acute-on-chronic liver failure patients[J]. Liver Int, 2023, 43( 2): 442- 451. DOI: 10.1111/liv.15361.
    [56]
    BRUYNSEELS K, SANTONI DE SIO F, van den HOVEN J. Digital twins in health care: Ethical implications of an emerging engineering paradigm[J]. Front Genet, 2018, 9: 31. DOI: 10.3389/fgene.2018.00031.
    [57]
    LI P, LIANG X, LUO JJ, et al. Omics in acute-on-chronic liver failure[J]. Liver Int, 2025, 45( 3): e15634. DOI: 10.1111/liv.15634.
    [58]
    JOHANSSON Å, ANDREASSEN OA, BRUNAK S, et al. Precision medicine in complex diseases-Molecular subgrouping for improved prediction and treatment stratification[J]. J Intern Med, 2023, 294( 4): 378- 396. DOI: 10.1111/joim.13640.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (793) PDF downloads(68) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return